The rise and fall of hepatitis C drug sales
Add Axios as your preferred source to
see more of our stories on Google.
Three years ago, Gilead Sciences was generating record sales and profits on the back of its hepatitis C pills. Now, Gilead's medicines are playing second fiddle to a competitor, and the drug that started it all, Sovaldi, has been relegated to a footnote.
The big picture: Gilead's drugs were a major reason why pharmaceutical spending shot up in 2014 and 2015, as patients flocked to the high-priced pills that cure the disease for a vast majority of people. Sales have gone down considerably, due to competing drugs and restrictive insurance coverage, even though a large number of hepatitis C patients remain untreated.
Between the lines: AbbVie has been the leading hepatitis C drugmaker for 2 consecutive quarters, as its Mavyret medicine has outsold Gilead's options, led by Epclusa and Harvoni.
- Gilead is still projected to collect roughly $3 billion in sales this year from its hepatitis C drugs, but that's a far cry from when it was getting almost $5 billion per quarter from hepatitis C drugs in 2015.
- Merck remains far behind AbbVie and Gilead in the market, even though it cut the price of Zepatier by 60% last year.
What we're watching: Whether more state Medicaid programs follow Louisiana and adopt a subscription approach to purchasing hepatitis C medications.
Go deeper: Inmates with hepatitis C aren't getting the medicine.
